(VIANEWS) – Cadence Design Systems (CDNS), Atlanticus Holdings Corporation (ATLC), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Cadence Design Systems (CDNS)
16.7% sales growth and 32.17% return on equity
Cadence Design Systems, Inc. provides software, hardware, services, and reusable integrated circuit (IC) design blocks worldwide. The company offers functional verification services, including emulation and prototyping hardware. Its functional verification offering consists of JasperGold, a formal verification platform; Xcelium, a parallel logic simulation platform; Palladium, an enterprise emulation platform; and Protium, a prototyping platform for chip verification. The company also provides digital IC design and sign off products, including Genus synthesis and Joules RTL power solutions, as well as Modus DFT software solution to reduce systems-on-chip design-for-test time; physical implementation tools, such as place and route, optimization, and multiple patterning preparation; and Innovus implementation system, a physical implementation system. In addition, it offers custom IC design and simulation products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and radio frequency designs; and system design and analysis products to develop printed circuit boards and IC packages, as well as to analyze electromagnetic, electro-thermal, and other multi-physics effects. Further, the company provides intellectual property (IP) products comprising pre-verified and customizable functional blocks to integrate into customer's ICs; and verification IP with memory models to emulate and model the expected behavior and interaction of standard industry system interface protocols. Additionally, it offers services related to methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company serves consumer, hyperscale computing, 5G communications, mobile, automotive, aerospace and defense, industrial, and life science industries. Cadence Design Systems, Inc. was incorporated in 1987 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Cadence Design Systems has a trailing twelve months EPS of $3.81.
PE Ratio
Cadence Design Systems has a trailing twelve months price to earnings ratio of 80.28. Meaning, the purchaser of the share is investing $80.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.17%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.2%, now sitting on 4.08B for the twelve trailing months.
Yearly Top and Bottom Value
Cadence Design Systems’s stock is valued at $305.85 at 20:22 EST, below its 52-week high of $327.36 and way above its 52-week low of $198.92.
Moving Average
Cadence Design Systems’s value is higher than its 50-day moving average of $300.11 and way above its 200-day moving average of $268.79.
2. Atlanticus Holdings Corporation (ATLC)
13.7% sales growth and 19.62% return on equity
Atlanticus Holdings Corporation provides credit and related financial services and products to customers the United States. It operates in two segments, Credit as a Service, and Auto Finance. The Credit as a Service segment originates a range of consumer loan products, such as private label and general purpose credit cards originated by lenders through various channels, including retail and healthcare, direct mail solicitation, digital marketing, and partnerships with third parties; and offers credit to their customers for the purchase of various goods and services, including consumer electronics, furniture, elective medical procedures, healthcare, educational services, and home-improvements by partnering with retailers and service providers. In addition, it offers loan servicing, such as risk management and customer service outsourcing for third parties; and engages in testing and investment activities in consumer finance technology platforms. The Auto Finance segment purchases and/or services loans secured by automobiles from or for a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here, and used car business. This segment also provides floor plan financing and installment lending products. Further, the company invests in and services portfolios of credit card receivables. Atlanticus Holdings Corporation was founded in 1996 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Atlanticus Holdings Corporation has a trailing twelve months EPS of $4.25.
PE Ratio
Atlanticus Holdings Corporation has a trailing twelve months price to earnings ratio of 6.4. Meaning, the purchaser of the share is investing $6.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.62%.
Volume
Today’s last reported volume for Atlanticus Holdings Corporation is 16582 which is 23.05% above its average volume of 13475.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 360.95M for the twelve trailing months.
3. BioMarin Pharmaceutical (BMRN)
13.7% sales growth and 4.22% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.06.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 76.33. Meaning, the purchaser of the share is investing $76.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.22%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.47B for the twelve trailing months.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $80.91 at 20:22 EST, way below its 52-week high of $99.56 and higher than its 52-week low of $76.02.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 20.7% and 123.8%, respectively.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 2257100 which is 47.18% above its average volume of 1533560.
4. Oxford Lane Capital Corp. (OXLC)
12.9% sales growth and 14.53% return on equity
Oxford Lane Capital Corp. is a close ended fund launched and managed by Oxford Lane Management LLC. It invests in fixed income securities. The fund primarily invests in securitization vehicles which in turn invest in senior secured loans made to companies whose debt is rated below investment grade or is unrated. Oxford Lane Capital Corp was formed on June 9, 2010 and is domiciled in the United States.
Earnings Per Share
As for profitability, Oxford Lane Capital Corp. has a trailing twelve months EPS of $0.66.
PE Ratio
Oxford Lane Capital Corp. has a trailing twelve months price to earnings ratio of 7.56. Meaning, the purchaser of the share is investing $7.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.53%.
Moving Average
Oxford Lane Capital Corp.’s worth is under its 50-day moving average of $5.07 and under its 200-day moving average of $5.07.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 279M for the twelve trailing months.
Volume
Today’s last reported volume for Oxford Lane Capital Corp. is 1881270 which is 10.6% below its average volume of 2104480.
Sales Growth
Oxford Lane Capital Corp.’s sales growth is 12.9% for the present quarter and 12.9% for the next.
5. STERIS (STE)
9.6% sales growth and 9.11% return on equity
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Earnings Per Share
As for profitability, STERIS has a trailing twelve months EPS of $5.69.
PE Ratio
STERIS has a trailing twelve months price to earnings ratio of 35.85. Meaning, the purchaser of the share is investing $35.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.11%.
Volume
Today’s last reported volume for STERIS is 549003 which is 23.88% above its average volume of 443167.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 3.5% and 6.5%, respectively.
